Trial Profile

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dinutuximab (Primary) ; Sargramostim (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Doxorubicin; Etoposide; Isotretinoin; Melphalan; Thiotepa; Topotecan; Vincristine
Indications Neuroblastoma
Focus Adverse reactions

Most Recent Events

17 Oct 2024 Planned End Date changed from 22 Sep 2024 to 22 Sep 2025.
22 Mar 2024 Planned End Date changed from 31 Dec 2023 to 22 Sep 2024.
14 Feb 2023 Planned End Date changed from 4 Jan 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com